Industry Profile: India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 percent of global demand for various vaccines, 40 percent of the generic market in the US, and 25 percent of all medications in the UK.

India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Over 80 percent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The pharmaceutical sector was valued at US$ 33 billion in 2017. The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4 percent over 2015–20 to reach US$ 55 billion. India’s pharmaceutical exports stood at US$ 17.27 billion in 2017-18 and are expected to reach US$ 20 billion by 2020. Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (USFDA) in 2017. The country accounts for around 30 percent (by volume) and about 10 percent (value) in the US$ 70-80 billion US generics market. India’s biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected to grow at an average growth rate of around 30 percent a year and reach US$ 100 billion by 2025. Biopharma, comprising vaccines, therapeutics, and diagnostics, is the largest sub-sector contributing nearly 62 percent of the total revenues at Rs 12,600 crore (US$ 1.89 billion).

Company Profile: DIVIS LAB is an India-based Active Pharmaceutical Ingredients (Apis) and Intermediates producer. The company was built in 1990 as a Divis research center with research and development as the prime objective. The organization is occupied with assembling bland Apis, a customs union of dynamic fixings, and other claims to fame chemicals, such as peptides and nutraceuticals. The organization has three multi-reason fabricating offices with an aggregate reactor limit of 4,500 cubic meters and all help foundations, for example, Utilities, environment administration, and security frameworks. The organization’s primary assembling and innovative work offices are found in Andhra Pradesh, India. The organization has two subsidiaries: DIVIS LAB (USA) Inc and Divi’s Laboratories Europe AG, in the wake of advertising Neutraceutical items in North American and European Countries.

Shareholding Pattern: BSE Data

Financials and ratio : [table id=134 /]

Future prospectus: Pharma sector was going through a painful time. Divis get EIR with six observations. It was among the top holding of some big mutual fund houses. Now, Sun pharma is also getting a sign of solving its problem of halol plant. So there is a chance that Divis will also come out of situations. There is hardly any problem other than this.